Literature DB >> 18942710

Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells.

Rebekka Wehner1, Bärbel Löbel, Martin Bornhäuser, Knut Schäkel, Marc Cartellieri, Michael Bachmann, Ernst Peter Rieber, Marc Schmitz.   

Abstract

Dendritic cells (DCs) display an extraordinary capacity to induce T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Additional findings indicate that DCs may also play a crucial role for the activation of natural killer (NK) cells, which are important effectors in innate antitumor immunity. However, studies investigating the interaction between native human DCs and NK cells are limited. Recently, we defined 6-sulfo LacNAc (slan) DCs as a major subpopulation of myeloid human blood DCs, which represent principal producers of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin (IL)-12. Functional data revealed that slanDCs efficiently induce neoantigen-specific CD4+ T cells and activate tumor-reactive cytotoxic T cells. When evaluating the crosstalk between slanDCs and NK cells in this study, we found that lipopolysaccharide (LPS)-activated slanDCs efficiently enhance NK cell CD69 expression and interferon (IFN)-gamma secretion. NK cell-mediated tumor-directed cytotoxicity was significantly improved by slanDCs. NK cell activation induced by slanDCs was critically dependent on IL-12. When investigating the impact of NK cells on the immunostimulatory capacity of slanDCs, we observed that they promote DC maturation. In addition, NK cells strongly enhanced the secretion of immunomodulatory IL-12 and reduced the release of immunosuppressive IL-10 by slanDCs. IFN-gamma and cell-to-cell contact contributed to these effects. Furthermore, data revealed that DC-NK cell crosstalk improves slanDC-mediated differentiation of naïve CD4+ T lymphocytes into IFN-gamma-producing Th1 cells. In conclusion, we demonstrate a reciprocal activating interaction between slanDCs and NK cells, which may play a pivotal role in the regulation of antitumor immunity. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18942710     DOI: 10.1002/ijc.23962

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Histamine H(4) receptor activation on human slan-dendritic cells down-regulates their pro-inflammatory capacity.

Authors:  Maria Gschwandtner; Knut Schäkel; Thomas Werfel; Ralf Gutzmer
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

2.  Rapid reconstitution of functionally active 6-sulfoLacNAc(+) dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplant.

Authors:  E Mimiola; O Marini; O Perbellini; A Micheletti; W Vermi; S Lonardi; C Costantini; E Meneghelli; A Andreini; C Bonetto; A Vassanelli; M Cantini; E Zoratti; D Massi; A Zamo'; A Leso; G Quaresmini; F Benedetti; G Pizzolo; M A Cassatella; C Tecchio
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  IL-1β limits the extent of human 6-sulfo LacNAc dendritic cell (slanDC)-mediated NK cell activation and regulates CD95-induced apoptosis.

Authors:  Dejene Milkessa Tufa; Fareed Ahmad; Debanjana Chatterjee; Gerrit Ahrenstorf; Reinhold Ernst Schmidt; Roland Jacobs
Journal:  Cell Mol Immunol       Date:  2016-04-18       Impact factor: 11.530

4.  Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma.

Authors:  Baptiste Lamarthée; Frédéric de Vassoigne; Florent Malard; Nicolas Stocker; Inès Boussen; Clémence Médiavilla; Ruoping Tang; Fanny Fava; Laurent Garderet; Zora Marjanovic; Eolia Brissot; Mohamad Mohty; Béatrice Gaugler
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

5.  Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Authors:  Marieta Toma; Rebekka Wehner; Anja Kloß; Linda Hübner; Georgia Fodelianaki; Kati Erdmann; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Barbara Seliger; Dorothee Brech; Elfriede Noessner; Torsten Tonn; Knut Schäkel; Martin Bornhäuser; Michael P Bachmann; Manfred P Wirth; Gustavo Baretton; Marc Schmitz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 6.  Dendritic cell-based immunotherapy for prostate cancer.

Authors:  Hanka Jähnisch; Susanne Füssel; Andrea Kiessling; Rebekka Wehner; Stefan Zastrow; Michael Bachmann; Ernst Peter Rieber; Manfred P Wirth; Marc Schmitz
Journal:  Clin Dev Immunol       Date:  2010-11-04

7.  Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.

Authors:  M Wemeau; O Kepp; A Tesnière; T Panaretakis; C Flament; S De Botton; L Zitvogel; G Kroemer; N Chaput
Journal:  Cell Death Dis       Date:  2010-12-02       Impact factor: 8.469

8.  Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

Authors:  Eva Lion; Sébastien Anguille; Zwi N Berneman; Evelien L J M Smits; Viggo F I Van Tendeloo
Journal:  PLoS One       Date:  2011-06-17       Impact factor: 3.240

Review 9.  Cellular-based immunotherapies for patients with glioblastoma multiforme.

Authors:  Xun Xu; Florian Stockhammer; Michael Schmitt
Journal:  Clin Dev Immunol       Date:  2012-02-28

10.  Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol.

Authors:  Ulrike Koehl; Claudia Brehm; Sabine Huenecke; Stefanie-Yvonne Zimmermann; Stephan Kloess; Melanie Bremm; Evelyn Ullrich; Jan Soerensen; Andrea Quaiser; Stephanie Erben; Claudia Wunram; Tanja Gardlowski; Eileen Auth; Torsten Tonn; Christian Seidl; Sandrine Meyer-Monard; Martin Stern; Jakob Passweg; Thomas Klingebiel; Peter Bader; Dirk Schwabe; Ruth Esser
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.